Search Results: "Martin shkreli"
-
Blue Cross settles class action suit naming ‘pharma bro’ Martin Shkreli for $28M
Shkreli controversially raised the price of the drug Daraprim, which is used to treat a potentially fatal parasitic infection, by 4,000%, from $13.50 to $750 per pill in 2015. In January, a federal judge banned him from the pharmaceutical industry for life.
-
Insurers sue ‘pharma bro’ Martin Shkreli, company for alleged price gouging
Blue Cross and Blue Shield of Minnesota has filed a class-action lawsuit — on behalf of itself and insurers from 30-plus states — against Martin Shkreli and Vyera Pharmaceuticals. The suit alleges the defendants intentionally monopolized the market for Daraprim to raise the price of the drug by more than 4,000%.
-
Sorry, Martin Shkreli: FDA approves first generic version of Daraprim
The drug, used to treat toxoplasmosis infection, became the subject of notoriety in 2015 when manufacturer Turing Pharmaceuticals, then led by Shkreli, raised the price from $13.50 to $750 per pill, making it a poster child for the issue of high drug prices.
-
Martin Shkreli, his former company thwarted generic competition against toxoplasmosis drug, FTC says
In charges announced Monday, the agency says Vyera Pharmaceuticals – formerly Turing Pharma – used deals with distributors to prevent generic companies from obtaining samples and sales data for Daraprim. Vyera called the charges meritless.
-
Report: Martin Shkreli runs his latest drug company from prison
The Wall Street Journal reported Thursday that the infamous former Turing Pharmaceuticals CEO was running the company with the aid of a contraband mobile phone.
-
Court finds “pharma bro” Martin Shkreli caused losses of more than $10M
The losses Martin Shkreli caused through securities fraud mean he could face several years in prison when he is sentenced next month.
-
Former attorney to pharma bro Martin Shkreli found guilty in fraud scheme
Evan Greebel acted as outside counsel for pharma company Retrophin from 2012 to 2014. Prosecutors alleged during that time Greebel assisted Martin Shkreli in using Retrophin’s assets to pay investors in unrelated hedge funds run by Shkreli through the use of phony settlement and consulting agreements.
-
Breaking: Martin Shkreli’s Clinton threat lands him in jail
A judge has revoked bail for the pharma bro, who is waiting to be sentenced for securities fraud, over comments he made on Facebook offering a $5,000 bounty for samples of hair from former Secretary of State and presidential candidate Hillary Clinton.
-
Prosecutors want Martin Shkreli to just shut the hell up
Although he has been “banned” from Twitter, by Twitter, Martin Shkreli is allegedly using other accounts to Tweet about the trial. He’s also holding impromptu press conferences.
-
5 of the best juror excuses in the Martin Shkreli case thus far
“In this particular case, the only thing I’d be impartial about is what prison he goes to,” said a potential juror on day three of Martin Shkreli’s high-profile court case, highlighting the challenge of jury selection.
-
KaloBios distancing itself from Martin Shkreli with new drug pricing model
In the wake of its relationship with Martin Shkreli, KaloBios’ new CEO Cameron Durrant “wants to clean up the messy legacy and start afresh,” he said.
-
Morning Read: Turing Pharma execs testify Martin Shkreli said, “No one cares about drug prices.”
Also, a potentially game changing approach to kidney transplants and Alphabet is selling is robotics business.
-
Martin Shkreli’s congressional hearing in photos
Did he seem uncomfortable, or was the notorious pharma dudebro trying to project the confidence that so often has veered into arrogance since he became the poster child for runaway price hikes last year?
-
Martin Shkreli threatens Wu-Tang Clan member in video
Martin Shkreli Shkreli talks about cocaine in a new video railing against Wu Tang Clan member Ghostface Killah. Perhaps he should be talking about clozapine instead.